Document is current
Any future updates will be listed below
-
Authors
Pistilli, Barbara https://orcid.org/0000-0002-9184-7199
Mosele, Fernanda https://orcid.org/0000-0001-7841-2900
Corcos, Noemie
Pierotti, Livia
Pradat, Yoann
Le Bescond, Loic
Lacroix-Triki, Magali https://orcid.org/0000-0002-6641-8536
Nachabeh, Ghada
Alfaro, Alexia
Catelain, Cyril
Job, Bastien https://orcid.org/0000-0002-2720-7664
Mami-Chouaib, Fathia https://orcid.org/0000-0001-9685-6011
Badel, Severine
Farace, Françoise https://orcid.org/0000-0001-8563-160X
Oulhen, Marianne
Kannouche, Patricia https://orcid.org/0000-0002-6050-3457
Tran, Diep T. N. https://orcid.org/0000-0002-3982-4221
Droin, Nathalie https://orcid.org/0000-0002-6099-5324
Vicier, Cecile
Frenel, Jean Sebastien https://orcid.org/0000-0002-5273-0561
D’Hondt, Veronique https://orcid.org/0000-0001-5238-4032
Dalenc, Florence
Bachelot, Thomas https://orcid.org/0000-0002-0866-9484
Ducoulombier, Agnes
Benderra, Marc Antoine
Loirat, Delphine
Mayeur, Didier
Deluche, Elise https://orcid.org/0000-0001-8474-3116
Deneuve, Jacqueline
Cheikh-Hussin, Rasha
Guyader, Pierre https://orcid.org/0009-0009-5767-3912
Signolle, Nicolas
Godefroy, Karine
Talbot, Hugues https://orcid.org/0000-0002-2179-3498
Vakalopoulou, Maria
Christodoulidis, Stergios https://orcid.org/0000-0002-8773-1070
Bernard, Elsa
Koudou, Yves
Sporchia, Andrea
Suto, Fumitaka https://orcid.org/0009-0009-5649-2650
Li, Lie
Sternberg, David W.
Michiels, Stefan https://orcid.org/0000-0002-6963-2968
André, Fabrice https://orcid.org/0000-0001-5795-8357
Sellami, Dalila
Montagnac, Guillaume
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 3 July 2025
First Online: 4 September 2025
Competing interests
: B.P. has received consulting fees from AstraZeneca (institutional), Seagen (institutional), Gilead (institutional), Novartis (institutional), Lilly (institutional), MSD (institutional), Pierre Fabre (personal) and Daiichi Sankyo (institutional or personal); research funding (to the institution) from AstraZeneca, Daiichi Sankyo, Gilead, Seagen and MSD; and travel support from AstraZeneca, Pierre Fabre, MSD, Daiichi Sankyo and Pfizer. F.M. has received consulting fees from Novartis and Pegascy. M.L.T. has received consulting fees from AstraZeneca and Daiichi Sankyo. J.S.F. has received consulting fees, honoraria for lectures and presentations and support for attending meetings from and participation on data safety monitoring for AstraZeneca, GSK, Eisai, MSD, Lilly, Pfizer, Novartis, Daiichi Sankyo and Seagen. M.A.B. has received consulting fees from Daiichi Sankyo; honoraria for lectures and presentations from Exact Sciences; support for attending meetings from Novartis, Lilly and Seagen; and participation on data safety monitoring for MSD, AstraZeneca, Novartis, Lilly, Esai, Exact Sciences, Daiichi and Sankyo. T.B. has received grants or contracts from other entities, such as AstraZeneca (institution), Pfizer (institution), SeaGen (institution) and Novartis (institution); honoraria for lectures and presentations from SeaGen, Novartis, Pfizer and Lilly; support for attending meetings from Roche, AstraZeneca, Daiichi Sankyo, Pfizer and Novartis; and participation on data safety monitoring for AstraZeneca, Daiichi Sankyo, SeaGen, Novartis, Pfizer and Lilly. J.D. has received consulting fees from Daiichi Sankyo and AstraZeneca. A.S., F.S., L.L., D.W.S. and D.S. are employees of Daiichi Sankyo. S.M. is a data and safety monitoring member of clinical trials for IQVIA, Kedrion, Biophytis, Servier and Yuhan and a scientific committee study member of an observational study for Roche. F.A. has received research funding and speaker or advisor honoraria (compensated to the hospital) for Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis and Eli Lilly. The remaining authors declare no competing interests.
